Takeda Pharmaceutical acquired the Baxalta biologics manufacturing facility in Minnesota. Takeda plans to use the facility primarily for the manufacture of Entyvio® (vedolizumab) and other biologic products.

“Takeda’s focus is providing patients access to quality therapies,” said Thomas Wozniewski, global manufacturing and supply officer at Takeda. “Acquiring the state of the art Brooklyn Park facility and gaining access to a highly experienced and dedicated team is a very important strategic benefit for Takeda that reinforces and expands upon our global operations for Entyvio and future biologic products.”

The acquisition will also provide long-term strategic benefits for Takeda through enhanced capacities for the manufacture of additional commercial products and investigational drugs under clinical development, noted Wozniewski, adding that this deal allows Takeda to establish and develop direct commercial bio-manufacturing expertise.








This site uses Akismet to reduce spam. Learn how your comment data is processed.